While we currently treat these patients as a single group defined simply as obese, the future will likely demand more personalized approaches, said DiMarchi
We uncover topics around weight loss, side effects of different GLP-1 RAs, and concerns about drug access and supply, with a mainly neutral-to-positive view of GLP-1 RAs, highlighting the role of an AI-enabled pipeline to help monitor for emerging side effects, uncover public sentiment, and guide future directions for research and public health efforts
If tirzepatide can reduce intracranial pressure enough to resolve headaches in IIH, it is plausible that it can reduce pressure enough to lower the migraine threshold in people without a formal IIH diagnosis
The mechanistic hypothesis: Semaglutide activates GLP-1R, appetite suppression, glycemic control Cagrilintide activates amylin receptors, appetite suppression via the area postrema, slowing of gastric evacuation Two independent mechanisms of appetite suppression a supra-additive effect In Phase 1b and Phase 2 trials the combination showed a stronger effect than either component alone : Semaglutide alone: 14.9 % (STEP-1) Cagrilintide alone (Phase 2): 10.8 % CagriSema combination (Phase 2): 15.6 % CagriSema Phase 3 (REDEFINE 1): 25.3 % CagriSema thus becomes the largest body-weight signal reported in the published incretin literature to date , stronger than Tirzepatide (22.5 % in SURMOUNT-1) and comparable to Retatrutide
But we dont need to go under the knife, or take a $1,000-a-month drug to decrap our diet
They help lower insulin resistance and encourage your cells to release more GLP-1